Fintech PR
Supira Medical Secures $120M Oversubscribed Series E Financing and Completes Enrollment of SUPPORT I Early Feasibility Study in the United States

LOS GATOS, Calif., March 26, 2025 /PRNewswire/ — Supira Medical, Inc. (Supira), a clinical-stage Shifamed portfolio company, today announced the successful completion of an oversubscribed Series E financing round, raising $120M to accelerate the company’s mission of transforming the percutaneous ventricular assist device (pVAD) market. The round was led by new investors Novo Holdings and Qatar Investment Authority (QIA), along with participation from two undisclosed strategic investors. Existing investors participated as well, including Cormorant Asset Management and The Capital Partnership (TCP), 415 Capital, AMED Ventures, PA MedTech VC fund, and Unorthodox Ventures. Funds will be used to expand Supira’s clinical programs for both high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock (CS). This clinical expansion includes the SUPPORT II U.S. Pivotal Study for HRPCI, which will be used to seek FDA PMA approval.
“We are grateful for the continued confidence and support from our current investors and delighted to welcome new world-class investors to this financing consortium,” commented Dr. Nitin Salunke, President and CEO of Supira Medical. “This significant capital raise underscores the team’s tremendous progress as we look forward to exciting opportunities ahead of us to improve clinical outcomes for both HRPCI and cardiogenic shock patients.”
Additionally, Supira welcomes Dr. Christopher Shen, Partner, Novo Holdings US to its Board of Directors. “We believe there is a massive unmet need for next-generation ventricular support devices to promote myocardial recovery and improve peripheral organ perfusion in HRPCI and CS patients,” stated Dr. Shen. “The Supira team has built a strong clinical foundation to further validate their advanced low-profile, high flow technology platform in two important segments of interventional heart failure, and we are pleased with their excellent progress bringing this therapy closer to market.”
The company recently completed enrollment of its U.S. SUPPORT I Early Feasibility Study (EFS), enrolling a total of 15 patients across four clinical sites. The prospective, single-arm clinical study evaluated the safety and feasibility of Supira’s innovative pVAD in patients undergoing HRPCI.
pVADs are important for supporting cardiovascular function during HRPCI, particularly in patients with complex coronary anatomy, compromised hemodynamics, and multiple comorbidities. They are also used in cardiogenic shock, a high-mortality condition where the heart is too weak to pump sufficient blood to vital organs, usually resulting from a heart attack or heart failure. The Supira System is an investigational device and is not approved for sale in the U.S. or anywhere in the world.
Piper Sandler acted as exclusive financial advisor and Sidley Austin LLP acted as legal counsel to Supira Medical in this transaction.
About Supira Medical, Inc.
Supira Medical, a clinical-stage Shifamed portfolio company, is focused on the development of a next-generation pVAD for use in high-risk patients undergoing interventional procedures and experiencing cardiogenic shock. To date, the Supira System has benefited 85 HRPCI patients. To learn more about Supira Medical, please visit www.supiramedical.com.
About Novo Holdings
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.
Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.
As of year-end 2023, Novo Holdings had total assets of EUR 149 billion. www.novoholdings.dk
About Qatar Investment Authority
QIA is the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term perspective that can deliver sustainable returns and contribute to the prosperity of the State of Qatar.
Media contact: media@qia.qa
About Shifamed, LLC.
Founded by serial entrepreneur Amr Salahieh, Shifamed is a highly specialized medical innovation hub focused on developing solutions that accelerate time to market, reduce risk, increase impact, and forge a path toward a world where patients are able to live longer, healthier lives. To learn more about Shifamed, please visit www.shifamed.com.
Media Contact:
Craig Brandli
VP of Marketing
craig@supiramedical.com
Logo – https://mma.prnewswire.com/media/1754758/SupiraMedical_Logo_Logo.jpg
Fintech PR
BSV Blockchain Highlights Blockchain Innovation at MERGE Buenos Aires

ZUG, Switzerland, April 2, 2025 /PRNewswire/ — Last week, BSV Association (BSVA) successfully participated as a Silver Sponsor at MERGE Buenos Aires, held from March 24th to 26th at the Palacio Libertad, Argentina. The event brought together leading industry experts to explore groundbreaking advancements in blockchain and Web3 technology.
As part of its commitment to driving financial inclusion and economic growth in Latin America, BSVA actively contributed to discussions on the future of blockchain applications.
Martin Coxall, Director of Growth at BSVA, participated in two key panel discussions:
- Stablecoins, CBDCs & Tokenised Cash: Implications in LatAm where discussions covered the opportunity with BSV blockchain in the region as well as the importance of monitoring the evolving regulatory situation in USA (Genius Act) & EU (MiCa).
- The Role of Web 3.0 in Modernising the State highlighting blockchain’s impact in solving societal issues in Latin America, such as identity and financial inclusion.
Martin shared that BSVA sees great potential in Argentina, Brazil and other LatAm countries, noting a growing interest in BSV with a relatively open approach to blockchain. There was significant government engagement from entities like the Central Bank of Argentina, CNV and El Salvador, as well as potential academic and strategic partnerships, including with UTN Buenos Aires and Cámara Argentina Fintech.
Eva Porras, Head of Education at BSVA delivered an insightful session titled, “Scaling for Good: How BSV is Shaping a Better World”. She highlighted how BSV’s key characteristics enable sustainable business solutions, emphasising its immutability, scalability, and cost-effectiveness as crucial for budgeting and risk management. She also introduced the new Teranode architecture, explaining its overlays and smart contract capabilities for diverse use cases. Finally, she noted how BSV ensures data integrity, fostering real knowledge and innovation to help build a better world.
Martin said, “MERGE Buenos Aires reaffirmed both the city’s and country’s commitment to digital transformation, with strong participation from government officials, blockchain experts, and industry leaders. BSVA remains dedicated to advancing the adoption of blockchain technology in Latin America and beyond.”
BSVA continues to promote trust, truth, and transparency in digital transactions, supporting the development of a more inclusive and efficient global economy.
About BSV Blockchain:
BSV Blockchain is a scalable and energy-efficient public blockchain designed for enterprise and government applications, offering unbounded scaling, low transaction fees, and robust security. BSV enables businesses to build innovative blockchain-based solutions. Focused on compliance and real-world utility, BSV supports smart contracts, tokenisation, and data integrity at a global scale. The BSV Association is a Swiss-based non-profit organisation, acting as the open-source governing body and global steward of the BSV Blockchain, dedicated to advancing its adoption and utility. It supports developers, enterprises, and governments in leveraging the BSV Blockchain.
Photo – https://mma.prnewswire.com/media/2656753/BSV_Association.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/bsv-blockchain-highlights-blockchain-innovation-at-merge-buenos-aires-302418800.html
Fintech PR
Sheikha Al Nowais Highlights Private Sector Leadership at IHIF 2025 in Berlin

UNWTO Secretary-General Candidate Emphasizes Execution, Partnership, and Regional Investment
BERLIN, April 2, 2025 /PRNewswire/ — Speaking at the prestigious International Hospitality Investment Forum (IHIF) in Berlin, Sheikha Al Nowais, candidate for Secretary-General of the UN World Tourism Organization (UNWTO), underscored the critical role of private sector leadership in shaping the future of global tourism.
In a series of high-level meetings with CEOs, institutional investors, and senior public officials, Ms. Al Nowais noted the overwhelming alignment around one central idea: the tourism industry needs leaders who bring real-world operational experience and the agility to navigate increasingly complex global market dynamics.
“The feedback I received—especially from long-standing champions of public-private collaboration—was clear,” said Al Nowais. “Now more than ever, tourism needs leadership with both vision and execution. The sector cannot afford to rely on bureaucracy alone—we must infuse policy with practical, commercial insight.”
Ms. Al Nowais, who has spent two decades in the private sector building sustainable tourism ventures across the Middle East and beyond, emphasized the importance of frameworks that are both innovative and grounded in delivery. She called for expanded investment partnerships in high-growth regions such as MENA, where tourism represents both a strategic economic lever and a vehicle for global cooperation.
The IHIF platform, which brought together hundreds of global hospitality leaders, offered a timely backdrop for Al Nowais’s candidacy, which champions regeneration, digital modernization, and inclusive governance as pillars of the next phase in tourism development.
“IHIF was an energizing reminder that this journey is not one we take alone,” she added. “What I saw in Berlin was a shared willingness to co-create the future of tourism—one built on resilience, opportunity, and partnership.”
ABOUT Sheikh Al Nowais
Sheikha Al Nowais is the only candidate in the current UNWTO Secretary-General race with deep private sector credentials and a track record of delivering on sustainability, crisis resilience, and inclusive growth. Her campaign is grounded in a reformist platform and seeks to reimagine tourism governance through equity, innovation, and action.
View original content:https://www.prnewswire.co.uk/news-releases/sheikha-al-nowais-highlights-private-sector-leadership-at-ihif-2025-in-berlin-302418781.html
Fintech PR
FDA Watch: The Quiet Gold Rush in AI-Powered Medical Devices

Equity Insider News Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, BC, April 2, 2025 /PRNewswire/ — Equity Insider News Commentary – Artificial Intelligence (AI) is quickly becoming a major force in healthcare, as use of AI applications in medical fields is growing rapidly. Researchers at Dartmouth recently conducted the first clinical trial of a therapy chatbot powered by generative AI (genAI), and found that it resulted in significant improvements in participants’ symptoms. Cleveland Clinic and UAE-based G42 recently started collaborating on the advancement of even more AI in healthcare adoption, signalling an international push in this revolution. Because of this, the market is paying even more attention to developers in tech that are adding tools to the mix, with recent updates coming from Avant Technologies, Inc. (OTCQB: AVAI), Apple Inc. (NASDAQ: AAPL), Amazon.com, Inc. (NASDAQ: AMZN), Spectral AI, Inc. (NASDAQ: MDAI), and GE HealthCare Technologies Inc. (NASDAQ: GEHC).
The article continued: Billionaire Bill Gates recently predicted that he thinks AI will make medical advice free and commonplace, changing healthcare at a rapid pace along the way. Private company Layer Health just raised a fresh $21 million to take on Healthcare AI’s scalability challenges, with investment from Define Ventures, Flare Capital Partners, GV and MultiCare Capital Partners.
Avant Technologies Partner, Ainnova, to Sponsor and Present at 2025 Healthcare Innovation Summit in Mexico City
Avant Technologies, Inc. (OTCQB: AVAI), an emerging leader in AI-driven healthcare innovation, continues to build momentum in the AI-driven healthcare sector through its joint venture with Ainnova Tech, developers of the Vision AI platform. Today, the two companies announced that Ainnova will sponsor and present at the 2025 Mexico Healthcare Innovation Summit—an international event focused on digital transformation and diagnostics.
Ainnova’s CEO, Vinicio Vargas, will present on preventative healthcare powered by artificial intelligence, highlighting the practical impact of its Vision AI platform on early disease detection, which the company recently began designing the clinical trial protocols for ahead of a pre-submission meeting with the US Food and Drug Administration (FDA).
Vargas’s appearance at the event reinforces a consistent strategy for Avant and Ainnova: increasing visibility across key international markets ahead of major regulatory milestones to come.
It also follows Ainnova’s recent strategic alignment with Apollo Hospitals in Southeast Asia, where the Vision AI platform has been cleared for commercial deployment in Brazil, and clinical pilots are being prepared across the Americas.
As previously mentiond, Ainnova is being guided by global CRO Fortrea ahead of the important pre-submission meeting with the FDA. The goal is to seek 510(k) clearance for Vision AI in detecting diabetic retinopathy, a gateway to broader use across multiple chronic disease categories.
Avant and Ainnova jointly control Ai-nova Acquisition Corp. (AAC), which holds global licensing rights to the technology portfolio, including proprietary retinal cameras and algorithms validated on more than 2.3 million clinical data points.
Between FDA progress, high-profile alliances, and a growing international presence, Avant Technologies continues to carve out a niche in the convergence of AI, diagnostics, and preventative care. Investors looking for small-cap exposure to the healthcare AI revolution may want to keep AVAI on the radar as these developments unfold.
CONTINUED… Read this and more news for Avant Technologies at:
Apple Inc. (NASDAQ: AAPL) is reportedly working on an AI-driven health coach, under the codename Project Mulberry, as a revamped version of its Health app. For a while now, CEO Tim Cook has been promising that Apple’s long-term plans include a big push into more health-related technologies.
According to Bloomberg’s Mark Gurman, Apple could launch this as early as next year alongside a future iOS update. The service would give users tips on diet and exercise, using data from the Health app and Apple devices like the Apple Watch.
It’s still unclear whether this tool will act more like a real medical assistant or just a health and wellness coach. Gurman describes it as an “AI doctor service,” and the report says it’s being trained using real data from doctors and medical professionals. The service might be called Health Plus and could become a major part of Apple’s growing services business.
Amazon.com, Inc. (NASDAQ: AMZN) is pushing deeper into genAI itself, including testing health assistants with a chatbot tool focused on health and wellness, called Health AI, which can answer health and wellness questions, “provide common care options for health care needs,” and suggest products.
Already, Amazon’s shopping chatbot, Rufus, can suggest products like ice packs and ibuprofen. Where Health AI goes further will be in providing users with medical guidance and care tips, such as how to deal with flu or cold symptoms. Health AI also steers users to Amazon’s online pharmacy, along with clinical services offered by One Medical, the primary care provider it acquired for roughly $3.9 billion in 2022.
Spectral AI, Inc. (NASDAQ: MDAI) recently announced strong results from its Burn Validation Study, showing that its DeepView® System outperformed burn physicians in identifying non-healing tissue.
“We believe these are excellent results and we are thrilled with the analysis of our DeepView System in our Burn Validation Study,” said Dr J. Michael DiMaio, M.D. “The DeepView System exceeded our expectations in terms of predictive performance. Following the FDA’s review, if authorized by the agency, our hope is that this tool will provide an objective and immediate prediction of non-healing burn tissue to expedite patient care and reduce system costs across the board. We look forward to bringing this predictive diagnostic tool to the United States marketplace as soon as possible.”
The study, one of the largest of its kind in the U.S., demonstrated DeepView’s superior accuracy using AI and multispectral imaging to assess burn wounds on day one. The company plans to submit the data to the FDA by mid-2025, aiming for De Novo Clearance and rapid commercialization.
GE HealthCare Technologies Inc. (NASDAQ: GEHC) recently unveiled its new Revolution™ Vibe CT system, featuring advanced AI-powered cardiac imaging that delivers fast, accurate scans—even in complex cases like atrial fibrillation or heavy coronary calcification. The system’s Unlimited One-Beat Cardiac imaging and AI-driven workflow aim to improve diagnostic speed, patient comfort, and operational efficiency across healthcare facilities.
“Expanding access to CCTA is crucial for managing the rising prevalence of CVD, ensuring timely and accurate diagnoses for a larger patient population,” shares Jean-Luc Procaccini, President and CEO, Molecular Imaging and Computed Tomography, GE HealthCare. “Our introduction of Revolution Vibe underscores our commitment to this mission. The system is designed to encourage the broader adoption of and access to cardiac imaging, combining advanced technology with AI-powered solutions to deliver fast, accurate diagnoses and a more comfortable patient experience. It is designed to empower healthcare providers to offer the highest quality care, even in the most challenging cases.”
With FDA-recommended CCTA adoption on the rise and cardiac disease still the leading global cause of death, Revolution Vibe is designed to expand access to life-saving imaging and reduce reliance on invasive procedures.
CONTACT:
Equity Insider
info@equity-insider.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Logo – https://mma.prnewswire.com/media/2644233/5249022/Equity_Insider_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fda-watch-the-quiet-gold-rush-in-ai-powered-medical-devices-302418684.html
-
Fintech7 days ago
Fintech Pulse: Your Daily Industry Brief – March 26, 2025 | Featuring Chime, Klarna, Unlock Technologies, Fenergos
-
Fintech PR6 days ago
Public Sector Pension Investment Board announces new Chief Financial Officer and new Chief Risk Officer
-
Fintech PR5 days ago
Transactions for persons discharging managerial responsibilities – CEO Jörg Brinkmann have purchased shares in H+H International A/S
-
Fintech5 days ago
Fintech Pulse: Your Daily Industry Brief – March 27, 2025 | Almond Fintech, Maplerad & More
-
Fintech PR5 days ago
Bybit Launches ‘Foolproof Fortune’ Event with 100,000 USDT Prize Pool and a Chance to Win a Luxury Watch
-
Fintech6 days ago
Fintech Pulse: Your Daily Industry Brief – March 27, 2025: Mercury, Jack Dorsey’s Startup, Grab Pay, Virginia, Straiker
-
Fintech PR4 days ago
BRI Holds 2025 Annual General Meeting of Shareholders (AGMS), Distributes IDR 51.73 Trillion in Dividends and Prepares for IDR 3 Trillion Buyback
-
Fintech PR5 days ago
AIM Congress 2025 to Spotlight AI’s Role in Business, Society, and Innovation with a Three-Day Conference